Skip to main content
 

Press Releases

August 18, 2016
New method reveals that repair outcomes are nonrandom at Cas9 cut sites DNA repair outcomes can be manipulated via modulation of the cellular DNA repair machinery
May 18, 2016

BERKELEY, Calif. -- May 18, 2016 -- Genus plc (LSE: GNS) (“Genus”), a global pioneer in animal genetics, and Caribou Biosciences, Inc. (“Caribou”), a leader in the revolutionary field of CRISPR-Cas gene editing, are pleased to announce a multi-year strategic collaboration where Genus receives a worldwide, exclusive license to Caribou’s leading CRISPR-Cas9 gene editing technology platform in certain livestock species. This is a significant move for Genus and marks the largest technology-driven alliance that Genus has made to date.

May 16, 2016

BERKELEY, CA – May 16, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. The financing included the participation of new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.  Also participating in the round were existing investors, including F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

March 24, 2016

BERKELEY, CA – March 24, 2016 – Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, announced today that co-founder Jennifer Doudna, Ph.D., and Rodolphe Barrangou, Ph.D., M.B.A., Chairman of Caribou’s Board of Directors, have been named as two of the winners of the 2016 Canada Gairdner Awards for their contributions in CRISPR-Cas characterization and gene editing.

February 23, 2016

BERKELEY, CA, and CORALVILLE, IA – February 23, 2016 – Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, and Integrated DNA Technologies, Inc. (IDT), a producer of custom synthetic oligonucleotide-based technologies for genomics applications, have entered into a non-exclusive license agreement under which Caribou has granted IDT worldwide rights to commercialize CRISPR-Cas9 reagents under Caribou’s intellectual property. The license is subject to a research use limited label.

Pages